NanoVector is a pre-clinical stage therapeutic drug company developing the world's first commercially viable biologic nanoparticle-based therapeutic drug delivery system. The NanoVector breakthrough technology is being used to develop a family of targeted drugs for late stage metastatic cancers using the plant virus nanoparticle (PVN). Effective targeting of chemotherapy has been highly sought after, because non-targeted chemotherapy causes considerable destruction of normal cells, resulting in severe adverse reactions. With targeting, anticancer agents can concentrate in a cancer cell resulting in extremely high efficacy, while reducing uptake of the anticancer agent by healthy cells; diminishing toxicity to normal cells and thus minimizing unpleasant side effects. The NanoVector drug delivery system is based on an engineered plant virus: Red clover necrotic mosaic virus (RCNMV). It is found in the human food chain, in such foods as cherries, and in some municipal water supplies in temperate climates. RCNMV is harmless to humans, will not replicate in a human cell, and has been found to be of low immunogenicity in testing of mice. It is a soil virus and one of the most robust viruses known. This plant virus has a 36 nanometer protein shell that with a hollow chamber that can be chemically opened and loaded with up to 1000 molecules of a small molecule drug. NanoVector's biologic nanoparticle has evolved for millions of years to become a quintessential intracellular delivery system that overcomes the manufacturing, loading, unloading and targeting technological challenges that plague other nanoscale delivery technologies. In addition, the PVN has two unique characteristics that make it nature's perfect drug delivery system. First and foremost of these unique characteristics, and an inherent property of the virus, is a built-in sensor-actuator system. When the therapeutic agent-carrying PVN enters a cell, it senses a change in chemical environment and automatically unloads its cargo. Therefore the highly toxic therapeutic agent is released only in a cell, never in the blood stream as with manmade particles that depend upon capsule degradation or require an external trigger to open the particles for the release of their contents. The second unique characteristic is a delayed drug release, enabling the PVN to travel deep within the cell prior to release, thereby avoiding efflux pumps in the cell membrane that could pump out the released drug. The biggest challenge in targeting cancer cells with a nanoparticle drug delivery system is identifying a cell surface receptor that is found on cancer cells but not targetable on healthy cells. NanoVector has successfully addressed this challenge by targeting the N-Cadherin cell surface receptor. In healthy cells N-cadherin is found in cell-to-cell junctions in the nervous system, opening the door for severe side effects if small molecule drugs or antibody-drug conjugates are used to target this molecular receptor. However the NanoVector nanoparticle is too large to enter the cell junctions of healthy cells, and therefore cannot target healthy cells. NanoVector has demonstrated that its PVN can effectively target N-cadherin on cancer cells but not in cell junctions between normal cells. The benefit derived from these features of the NanoVector nanoparticle and N-Cadherin targeting is the minimization of the horrendous side effects associated with free anti-cancer drugs in the blood stream.
Missing: NanoVector's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NanoVector's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing NanoVector
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
NanoVector is included in 2 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest NanoVector News
Nov 23, 2022
(Información remitida por la empresa firmante) OSLO, Norway, Nov. 23, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") will host a webcast, including a question and answers session on Thursday, November 24 at 4.30 P.M. CET. Reference is made to the stock exchange announcement regarding the Company comments on the proposed merger with APIM Therapeutics November 21. A webcast will be held as described below: Participation details In order to listen to the presentation, visit the Company's website www.nordicnanovector.com and click on the link to "Webcast", or sign up and access directly via the webcast link below: We encourage viewers to register for the webcast 5-10 minutes prior to the presentation. The presentation will be held in English. A Q&A session in both English and Norwegian will be held after the presentation. Information on how to submit questions will be given at the beginning of the session. Any questions may be submitted to email@example.com in advance. The presentation material will be made available on www.nordicnanovector.com and a replay of the webcast will also be made available at this website. Participants from The Company and APIM Therapeutics Jan H. Egberts Important information This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. Matters discussed in this announcement constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although Nordic Nanovector believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. Nordic Nanovector undertakes no obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities. View original content: enlace Comunicados Si quieres mejorar el posicionamiento online de tu marca, ahora puedes publicar tus notas de prensa o comunicados de empresa en la sección de Comunicados de europa press
NanoVector Frequently Asked Questions (FAQ)
Where is NanoVector's headquarters?
NanoVector's headquarters is located at Box 98385, Raleigh.
What is NanoVector's latest funding round?
NanoVector's latest funding round is Grant.
How much did NanoVector raise?
NanoVector raised a total of $130K.
Who are the investors of NanoVector?
Investors of NanoVector include National Science Foundation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.